Latest Biotech News

Researchers led by Trey Ideker at the University of California San Diego introduced MutationProjector, an AI foundation model designed to interpret tumor mutational landscapes and predict...

NICE issued updated guidance that supports payer reimbursement for Genmab’s tisotumab vedotin (Tivdak), an antibody-drug conjugate for recurrent or metastatic cervical cancer. The decision...

ClearNote Health raised $52 million in Series D financing, bringing total capital raised to more than $185 million. The round was led by founding investor Mattias Westman with participation...

A new editorial/analysis piece highlights how drug discovery teams are positioning for the “next wave” of proximity degraders—molecular approaches intended to bring targets into degradative...

Parse Biosciences and Bit.bio announced a collaboration to build a transcription factor-driven cell identity map covering cell state and cell fate. The partners will combine Bit.bio’s Opti-ox...

Waypoint Bio, a New York City startup, raised $20 million in Series A funding to run multiple CAR-T trials in China. The financing supports testing across cell therapy programs and leverages...

EMA’s CHMP recommended approval for camizestrant (Etcamah camizestrant) from AstraZeneca in combination with a CDK4/6 inhibitor for ER+/HER2- ESR1-mutant advanced or metastatic breast cancer that...

The Biopharma Sentiment Index (BPSI) for Q2 2026 climbed to 96 from 90 in Q1 and 78 in Q4 2025, bringing conditions closer to the neutral 100 line for the first time in years. The report points to...

The FDA has delayed its ruling on AstraZeneca’s camizestrant (camizestrant) breast cancer drug after a negative advisory committee vote, pushing the agency’s decision to consider new analyses...

Eli Lilly reported additional early trial results for VERVE-102, its PCSK9 base editing gene therapy acquired from Verve Therapeutics. In Phase 1b data described by Lilly, a single infusion...

Eli Lilly agreed to acquire three vaccine developers—Curevo, LimmaTech Biologics, and Vaccine Company—in coordinated transactions totaling up to nearly $3.8 billion. The moves broaden Lilly’s...

Cardiovascular biotech Kardigan filed for a Nasdaq initial public offering to fund development of a phase 2b/3 cardiac myosin activator, danicamtiv, plus additional late-stage opportunities. The...

Researchers unveiled a machine learning system designed to deliver just-in-time, risk-stratified sepsis evaluations inside neonatal intensive care units. The system targets earlier recognition...

A research team developed cryopreservable dopaminergic progenitors derived from human induced pluripotent stem cells and reported early functional restoration in Parkinsonian rat models after...

Researchers reported that platinum–antibody conjugates can enhance tumor recognition by the immune system, aiming to address a central limitation of immune checkpoint inhibitors: only a subset of...

Lund University researchers developed a blood test aimed at identifying early indicators of breast cancer recurrence by detecting circulating tumor DNA fragments before conventional imaging or...

A set of reports highlighted incremental but operationally important improvements to care delivery and monitoring. In women’s health, Aspira Women’s Health inked a deal with Cleveland Clinic to...

The FDA granted accelerated approval to Beqalzi (sonrotoclax), marking the first BCL2 inhibitor specifically approved for relapsed or refractory mantle cell lymphoma after at least two prior...

Eli Lilly agreed to acquire three vaccine developers in deals worth up to nearly $4 billion, positioning the company to expand beyond its core cardiometabolic franchise into infectious-disease...

Eli Lilly reported additional early Phase 1b results for VERVE-102, a one-time PCSK9 base-editing therapy acquired from Verve Therapeutics. In the company’s update, a single infusion reduced...